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Abstract
On the basis of their large specific surface areas, high adsorption and cation exchange capacities, swelling potential and low
toxicity, natural smectite clays are attractive substrates for the gastric protection of neutral and cationic drugs. Theophylline is an
amphoteric xanthine derivative that is widely used as a bronchodilator in the treatment of asthma and chronic obstructive
pulmonary disease. This study considers the in vitro uptake and release characteristics of the binary theophylline-smectite system.
The cationic form of theophylline was readily ion exchanged into smectite clay at pH 1.2 with a maximum uptake of 67 ±
2 mg g−1. Characterisation of the drug-clay hybrid system by powder X-ray diffraction analysis, Fourier transform infrared
spectroscopy, differential scanning calorimetry and scanning electron microscopy confirmed that the theophylline had been
exclusively intercalated into the clay system in an amorphous form. The drug remained bound within the clay under simulated
gastric conditions at pH 1.2; and the prolonged release of approximately 40% of the drug was observed in simulated intestinal
fluid at pH 6.8 and 7.4 within a 2-h timeframe. The incomplete reversibility of the intercalation process was attributed to
chemisorption of the drug within the clay lattice. These findings indicate that smectite clay is a potentially suitable vehicle for
the safe passage of theophylline into the duodenum. Protection from absorption in the stomach and subsequent prolonged release
in the small intestine are advantageous in reducing fluctuations in serum concentration which may impact therapeutic effect and
toxicity.
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Introduction
Aluminosilicate clays are widely used in the pharmaceutical
industry as stabilising and suspending agents, rheology mod-
ifiers and texture enhancers in various dosage forms [1, 2].
Smectites (a.k.a. bentonites) are a family of 2:1 clays whose
principal repeating layer system comprises an octahedral mag-
nesium or aluminium oxide sheet bound between two
tetrahedral silicate sheets [1]. In montmorillonite,
(Na,Ca)0.33(Al,Mg)2(Si4O10)(OH)2·nH2O, two thirds of the
octahedral sites are occupied by Al3+ ions, and in saponite,
Ca0.25(Mg,Fe)3((Si,Al)4O10)(OH)2·n(H2O), the octahedral
sites are fully occupied by Mg2+ ions. Lattice substitution of
Mg2+ for Al3+ in montmorillonite, and Al3+ for Si4+ substitu-
tion in saponite, confers a negative charge on the layers which
is balanced by labile interlayer Na+ and Ca2+ cations. In addi-
tion to the charge-balancing cations, water molecules are also
present between the layers, both of which are readily
exchangeable.
Montmorillonite, saponite and their mixtures are popu-
lar options in clay-drug hybrid controlled release systems
for oral, transdermal and topical administration [1–5].
Cationic drugs are particularly suitable for intercalation
within these clays, as they are conveniently exchanged
for the interlayer cations and their subsequent electrostatic
interaction with the negatively charged layers extends
their release. In addition to modified release, intercalation
within the clay can also afford protection from selected
in vivo environments such as gastric acidity.
Theophylline, C7H8N4O2, is a xanthine derivative
(shown in Fig. 1) which acts as an adenosine receptor
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antagonist and phosphodiesterase inhibitor [6]. It is used
as a bronchodilator in the treatment of asthma and chronic
obstructive pulmonary disease. Common adverse effects
include nausea, vomiting, diarrhoea, hypokalaemia, rhab-
domyolysis, ventricular arrhythmia, tachycardia and sei-
zures [7]. Theophylline is 90–100% bioavailable. Its ther-
apeutic serum concentration range is 5–20 mg dm−3 and it
possesses a relatively short half-life of approximately 6 h
[6, 8]. Accurate prediction of the required dose is compli-
cated by large interpatient variability in absorption and
elimination rates [6, 8]. For example, elevated gastric
acidity is known to enhance the absorption of theophyl-
line in the stomach which is associated with increased
side effects and high fluctuations in serum concentration
[8].
Recent studies have indicated that the incorporation of
smectite clays in multicomponent theophylline formula-
tions can provide sustained release which affords the po-
tential to reduce both dosing frequency and adverse ef-
fects [3, 9]. The principal objective of the present study
was to determine whether the intercalation of theophylline
in smectite clay is able to protect the drug from the acidic
gastric environment and to enable its controlled release in
the small intestine. The uptake kinetics of theophylline by
a commercial pharmaceutical grade smectite clay
(VEEGUM®, Vanderbilt Minerals, LLC, CT, USA) were
monitored as a function of theophylline concentration.
Equilibrium uptake isotherms were obtained as functions
of both theophylline and smectite concentrations. The na-
ture of the drug-clay interactions were determined by
powder X-ray diffraction analysis, Fourier transform in-
frared spectroscopy, differential scanning calorimetry and
scanning electron microscopy. The release profiles of the-
ophylline from the drug-clay hybrid were obtained in
phosphate-buffered saline at pH 7.4, simulated gastric
fluid at pH 1.2 and simulated intestinal fluid at pH 6.8
and 7.4.
Materials and methods
Materials and characterisation
The smectite clay (SM) used in this study was supplied by
Vanderbilt Minerals, LLC (Norwalk, CT, USA) and is com-
mercially available as VEEGUM®F. VEEGUM®F is a phar-
maceutical grade mixture of natural montmorillonite and sap-
onite clays that has been ‘micronized’ to a mean particle size
of 100 μm [10]. The smectite was heated at 100 °C in air prior
to use to remove adsorbed water. Theophylline (TP) was pur-
chased from BASF (Ludwigshafen am Rhein, Germany) in
the form of a white anhydrous powder with a purity of > 99%.
All other analytical grade reagents were obtained from Fisher
Scientific (Loughborough, UK) and used as received.
The crystalline structures of the smectite clay and theoph-
ylline drug were confirmed by powder X-ray diffraction anal-
ysis (XRD) using a Bruker D8 ADVANCE diffractometer
with Cu Kα = 1.5406 Å at a step size of 0.02° in the 2θ range
from 2 to 70° and a measuring time of 140 s per step. Fourier
transform infrared (FTIR) spectra of the clay and drug were
acquired using a Perkin Elmer Spectrum Two spectrometer
between 450 and 4000 cm−1 wavenumbers, with 10 scans at
a resolution of 4 cm−1. Secondary electron images were ob-
tained from uncoated samples attached to carbon tabs on an
Hitachi SU8030 scanning electron microscope with an accel-
erating voltage of 0.7 kV. Differential scanning calorimetry
was carried out on the clay and drug using a Mettler-Toledo
DSC823e calorimeter. Thermograms were collected on 2–
3 mg of material in sealed, pierced aluminium pans between
25 and 300 °C at a heating rate of 10 °Cmin−1 under nitrogen.
Theophylline uptake
The initial rates of uptake of theophylline by the smectite clay
were determined by batch sorption at 50 °C as functions of
theophylline concentration. In each case, 1.25 g of smectite
were dispersed in 25 cm3 of 0.1 N HCl(aq) at pH 1.2 by son-
ication for 30 min to enable the clay to swell. 25, 50, 75, 125
or 175 mg of theophylline were then added to the suspension
under stirring at 250 rpm (to produce samples labelled;
TP20SM, TP40SM, TP60SM, TP100SM and TP140SM, re-
spectively, where the number indicates the TP/SM ratio in
mg g−1). Contact times for specimens were at 30-s intervals
for 5 min, after which, the supernatant liquors were recovered
by centrifugation at 7500 rpm for 2 min and subsequent fil-
tration with a 0.45-μm syringe filter. The concentration of
theophylline remaining in solution was then determined by
UV-vis spectroscopy at 270 nm using an Hitachi U-2900Fig. 1 The structure of theophylline
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spectrophotometer [2]. Each experiment was carried out in
triplicate and the uptake of theophylline by smectite was cal-
culated by dividing the difference between the initial and final
masses of theophylline in solution (in mg) by the mass of
smectite present (in g).
Isotherm analysis of the uptake of theophylline by smectite
as a function of theophylline concentration was carried out by
batch sorption at 50 °C. The procedure described above was
repeated with a contact time of 60 min for each sample type to
obtain equilibrium uptake data which were then plotted
against initial theophylline concentration. Additionally, in
each case, the theophylline-loaded clay particles were recov-
ered, washed five times with 0.1 N HCl(aq) and dried at 60 °C
in air to constant mass. The recovered clay-drug hybrid mate-
rials were stored in air-tight polypropylene containers at room
temperature for characterisation by XRD and DSC analyses
(as outlined previously). A dried sample of the swollen smec-
tite (SM-H2O) following immersion in 0.1 N HCl(aq) at pH 1.2
for 30 min was also analysed by XRD, FTIR and DSC for
comparison.
Isotherm analysis of theophylline uptake as a function of
smectite concentration was also carried out at 50 °C under the
same experimental conditions described previously. Thus, iso-
therm data were collected from batch sorption experiments of
varying smectite concentration (5, 10, 20, 30, 40 and
50 mg cm−3) at a constant initial theophylline concentration
of 3 mg g−1 with a contact time of 60min. Again, in each case,
the equilibrium extent of theophylline uptake by smectite was
calculated via a simple mass balance for theophylline.
In vitro release of theophylline
The theophylline-smectite hybrid (viz. TP60SM) selected for
the in vitro release study was prepared by the batch sorption
method described above using 50 mg cm−3 of smectite
suspended in 0.1 N HCl(aq) containing 3 mg cm
−3 of theoph-
ylline at 50 °C for 60 min. The clay-drug hybrid was recov-
ered by centrifugation, washed five times with 0.1 N HCl(aq)
and dried at 60 °C in air to constant mass prior to characteri-
sation by XRD, FTIR, SEM and DSC and in vitro release
analysis.
In vitro release of theophylline from the drug-clay hybrid
was monitored in phosphate-buffered saline (PBS) at pH 7.4
[11], simulated gastric fluid (SGF) at pH 1.2 [12] and simu-
lated intestinal fluid (SIF) at pH 6.8 and 7.4 [13].
Theophylline release was also observed in modified SIF dis-
solution media to which were added either 8.0 mg cm−3 NaCl
(i.e. the quantity present in PBS) or 0.4 mg cm−3 NaCl (i.e. a
smaller incremental quantity), viz. SIF-8.0 and SIF-0.4, re-
spectively, to investigate the influence of ionic concentration
on the release behaviour. The principal compositions of the
dissolution media used in this study are listed in Table 1, and it
should be noted that the final pH values were achieved by
additions of either 0.2 M HCl(aq) or 0.1 M NaCl(aq).
Theophylline release profiles were obtained by suspending
200 mg of the drug-clay hybrid in 250 cm3 of the selected
dissolution medium under continuous stirring at 100 rpm.
Three cubic centimetre aliquots of the supernatant were
withdrawn, filtered through 0.45-μm syringe filters and
analysed by UV-vis spectroscopy at intervals up to 180 min.
At each interval, the withdrawn aliquot was replaced by 3 cm3
of fresh medium, and the appropriate correctionwas applied to
the calculation of the percentage of theophylline released from
the hybrid. Each experiment was carried out in triplicate.
Results
Characterisation of smectite
The powder XRD patterns of randomly orientated samples of
the commercial pharmaceutical grade smectite clay used in
this study after drying at 100 °C (SM) and after swelling in
water (SM-H2O) are shown in Fig. 2. These XRD patterns are
consistent with those in the literature for other smectite mix-
tures comprising montmorillonite and saponite [14–16]. The
basal spacing of anhydrous smectite is typically 10 Å which
increases incrementally to 12.5, 15.5 and 18.5 Å with the
incorporation of 1, 2 and 3 homogeneous water layers be-
tween each of the aluminosilicate sheets [15]. The basal spac-
ings of SM and SM-H2O are ~ 11 and 12.2 Å, respectively,
indicating that the dried, as received, clay is not entirely an-
hydrous and that the water-swollen clay used for the uptake of
theophylline possesses less than one complete water layer.
The very broad basal reflections observed for both SM and
SM-H2O are indicative of poor organisation of the layers in
the c-axis direction.
The FTIR spectra of SM and SM-H2O, shown in Fig. 3,
typify those of smectite clays [16, 17]. Stretching modes of
structural hydroxyl groups are assigned to the discrete signal
at 3615 cm−1 and those of adsorbed and bound water appear as
a very broad signal centred around 3440 cm−1 [16, 17].
Table 1 Compositions of dissolution media per cubic decimetre
[11–13]
Dissolution medium PBS SGF SIF SIF-8.0 SIF-0.4
NaCl (g) 8.0 – – 8.0 0.4
KCl (g) 0.2 3.73 – – –
KH2PO4 (g) 0.24 – 6.85 6.85 6.85
Na2HPO4 (g) 1.44 – – – –
NaOH (g) – – 0.896 0.896 0.896
0.2 M HCl(aq) (cm
3) – 425 – – –
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Bending modes of water occur at 1625 cm−1, and the signal at
1445 cm−1 is attributed to trace quantities of calcium carbon-
ate. Various Si-O-Si lattice vibrations give rise to the bands at
990, 800 and 690 cm−1, and the signal at 525 cm−1 is assigned
to Si-O-Al modes.
As anticipated, the DSC thermograms of SM and SM-H2O,
presented in Fig. 4, are essentially uneventful with the excep-
tion of the endothermic removal of adsorbed water between
40 and 130 °C. Understandably, the endotherm is greater in
the case of the more hydrated clay, SM-H2O.
Secondary electron images of SM (Fig. 5) show that this
material is highly polydispersed with granules of varying as-
pect ratio and maximum particle dimension of approximately
100 μm. Higher magnification also reveals the platy texture of
the clay particles within the granules.
Characterisation of theophylline
The powder XRD pattern of theophylline (TP) shown in Fig. 2
and the sharp melting point at 271 °C in the corresponding
DSC curve (Fig. 4) both confirm that the material used in this
study is pure crystalline anhydrous theophylline [18, 19]. The
FTIR spectrum of theophylline (Fig. 3) also closely resembles
those in the scientific literature [19, 20]. Various bands in the
region 3440–2460 cm−1 are assigned to the stretching modes
of the N-H group and to the aliphatic and aromatic C-H bonds
present in theophylline. Characteristic stretching of the car-
bonyl groups occurs at 1710 and 1665 cm−1 and the amine
N-H stretching gives rise to the signal at 1565 cm−1.
Uptake of theophylline by smectite
The rates of uptake of theophylline by the smectite clay at
pH 1.2 as functions of theophylline concentration are plotted
in Fig. 6. The initial rate of uptake is seen to increase with
theophylline concentration, and in all cases, equilibrium is
achieved within 1 min. Below pH 4, the imine nitrogen atom
of theophylline becomes protonated and the resulting cation is
stabilised by the electron resonance of the five-membered ar-
omatic ring and inductive effects [21]. The rapid uptake of
theophylline by smectite at pH 1.2 is indicative of the
Fig. 2 Powder XRD patterns of theophylline, smectite and clay-drug
hybrids
Fig. 3 FTIR spectra of theophylline, smectite and clay-drug hybrids
Drug Deliv. and Transl. Res.
favourable electrostatic interaction between the protonated
cationic form of the drug and the negatively charged clay
sheets. It should be noted that the mechanism of interaction
between smectite clays and theophylline is reported to proceed
via a two-step process which involves initial rapid cation ex-
change followed by chemisorption [22].
The equilibrium uptake of theophylline as a function of
smectite concentration is shown in Fig. 7. The quantity of
adsorbed drug per unit mass of smectite decreases non-
linearly with increasing smectite concentration which
indicates that the clay presents multiple adsorption sites of
differing energy. The concentration of smectite that gives the
lowest drug-clay loading per unit mass of clay (i.e.
50 mg cm−3) was selected for further isotherm analysis. The
rationale for this choice is that this system possesses the most
energetically uniform drug-clay interactions. Under the select-
ed batch conditions, a Langmuir-type isotherm is obtained for
the equilibrium uptake of theophylline as a function of drug
concentration (Fig. 8) and demonstrates that the maximum
loading capacity for this drug-clay system is 67 ± 2 mg g−1.
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Characterisation of theophylline-smectite hybrid
Samples corresponding to alternate points on the isotherm
plotted in Fig. 8 were characterised by XRD, FTIR and DSC
to determine the nature of the drug-clay interaction. Drug-clay
hybrids, TP20SM, TP60SM and TP140SM, were prepared by
contacting 50 mg cm−3 smectite with 1, 3 or 7 mg cm−3 solu-
tions of theophylline, respectively, for 60 min.
Powder XRD patterns of TP20SM, TP60SM and
TP140SM are shown in Fig. 2. The basal spacing of the smec-
tite is seen to increase to 14.3 Å for all hybrid samples, dem-
onstrating that the drug is intercalated within the clay. The
sharp principal reflections for crystalline theophylline (at
2θ = 7.21, 12.69 and 14.36°) are absent from these XRD
traces, and a weak broad signal at 13.59° arises from the in-
tercalation of the drug. The comparatively sharp basal reflec-
tions of the drug-intercalated smectite samples indicate a su-
perior stacking order along the c-axis relative to that of the
original clay. DSC analysis confirms the absence of a theoph-
ylline melting event within the hybrid systems demonstrating
that the intercalated drug is present in an amorphous form
(Fig. 4). Secondary electron images of sample TP140SM are
shown in Fig. 5 and illustrate that the larger granules tend to
disintegrate during the drug intercalation process. However,
the platy morphology of the clay appears unaffected by
intercalation and there is no evidence for the precipitation of
theophylline on the surface of the clay platelets.
Characteristic stretching vibrations of the carbonyl groups
of theophylline are present in the FTIR spectra of the drug-
clay hybrids (Fig. 3) at 1710 and 1665 cm−1 which are par-
tially obscured by the bending modes of water in the clay. A
shift in the position of the amine stretching signal of the hy-
brids relative to that of crystalline theophylline is observed
from 1565 to 1578 cm−1. This may be attributed to the elec-
trostatic interaction between the drug and clay; although, this
cannot be fully confirmed as shifts may also arise from the
protonation of the drug and its phase change from the crystal-
line to the amorphous state.
In vitro release of theophylline from the drug-clay
hybrid
The in vitro release behaviour of theophylline from drug-clay
hybrid TP60SM was monitored in PBS, SGF and SIF at
pH 6.8 and pH 7.4 (which represent the environments of the
duodenum and ileum, respectively). This hybrid has a drug
loading of 57 ± 2mg g−1 and was selected for the release study
as it represents the most energetically uniform adsorption
system with a loading below the theoretical maximum value
(to prevent any ‘initial burst’ of loosely adsorbed drug).
Under the selected experimental conditions, theophylline is
steadily released in PBS at pH 7.4 to a maximum extent of
80% after 60 min (Fig. 9a). The release profile does not con-
form to a simple diffusion model which indicates that the
complex nature of interactions between the drug and clay
lattice dictate the release behaviour [3, 22].
No detectible release of theophylline was observed from
the drug-clay hybrid in simulated gastric fluid at pH 1.2 during
an extended 72-h observation period. This finding demon-
strates that the intercalation of theophylline in smectite at
pH 1.2 is not readily reversible at the same pH despite the
presence of potentially exchangeable K+ cations in the super-
natant liquor.
The release profiles of theophylline in simulated intestinal
fluid at pH 6.8 and at pH 7.4 are plotted in Fig. 9b, c,
Fig. 6 Uptake profiles of theophylline by smectite as functions of
theophylline concentration
Fig. 7 Equilibrium uptake of theophylline as a function of smectite
concentration
Fig. 8 Equilibrium uptake of theophylline as a function of theophylline
concentration
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respectively. These data show that theophylline is released
more rapidly at the higher pH with a maximum release of
43% after 60 min. Incremental dissolution of the drug at
pH 6.8 continued throughout the 3-h observation period to
give a maximum release of 41%.
Since the maximum release of theophylline in SIF is ob-
served to be approximately 50% lower than that in PBS, the
composition of SIF was modified to match the Na+ ion con-
centration of PBS (by addition of 8.0 mg cm−3 of NaCl). SIF
was also prepared with the addition of a relatively low level
(0.4 mg cm−3) of Na+ ions to determine the influence of con-
centration of this potentially exchangeable cation on the re-
lease of the drug. Accordingly, the release of theophylline in
SIF-8.0 and SIF-0.4 at pH 7.4 and pH 6.8 is plotted in Fig. 9b,
c, respectively. In both cases, the rate of release was enhanced
as the Na+ ion concentration increased, with this effect being
more pronounced at pH 6.8. It is clear that the mass action of
cations in the supernatant solution accelerates the release of
the drug, but has little impact on the ultimate quantity of
theophylline that is discharged from the clay. Again, none of
the release profiles obtained in the various SIF media
conformed to a simple diffusion model [3, 22].
At present, the reason for the superior release of theophyl-
line in PBS compared with that in the original and modified
SIFmedia is unknown, but presumably relates to the influence
of different concentrations of anionic phosphate species pres-
ent in these liquors (Table 1).
Discussion
The large specific surface area, high adsorption and cation
exchange capacities, swelling potential and low toxicity of
smectites have been exploited in a wide range of formulations
for modulating drug delivery [1–5, 9, 16]. They are particu-
larly suitable for the gastric protection of cationic drugs and
are also under consideration as gastrointestinal decontamina-
tion agents to mitigate the absorption of ingested toxins [23].
The protonated cationic forms of basic and amphoteric
ionisable drugs (pKa > 7) are readily intercalated between
the negatively charged sheets of smectite clays under aqueous
acidic conditions [23, 24]. At low pH, such as that encoun-
tered in the stomach, the cationic form of the drug persists and
the strong electrostatic drug-clay interactions continue to bind
the drug to the clay matrix preventing its release. In addition,
subsequent to the initial intercalation by ion exchange, the
drug may become chemisorbed to the clay which will ulti-
mately limit the maximum extent to which the drug can be
released [22].
A number of recent studies reports the release of theophyl-
line from multicomponent formulations containing smectite
clays among numerous other constituents such as polymers,
hydrogels and other common excipients [2, 3, 9]. However,
there is a surprising paucity of information on the binary
theophylline-smectite system in the current literature [22, 23].
The present study demonstrates that the maximum uptake
of theophylline by the selected commercial pharmaceutical
grade smectite at pH 1.2 was 67 ± 2 mg g−1. This is consistent
with the findings of Mináriková et al. [23] who report the
same maximum loading of theophylline in a different com-
mercial smectite clay under simulated gastrointestinal
conditions.
The present study also confirms that the adsorbed theoph-
ylline was exclusively intercalated into the clay lattice in an
amorphous form which was not released under simulated gas-
tric conditions (at pH 1.2). As previously mentioned, en-
hanced absorption of theophylline from the stomach is asso-
ciated with increased side effects and high fluctuations in se-
rum concentration, and in this respect, smectite clay affords a
potentially suitable vehicle for the passage of the drug into the
small intestine. Indeed, approximately 40% of the intercalated
theophylline was steadily released into simulated intestinal
Fig. 9 Release profiles of theophylline in a PBS, b SIF at pH 6.8 and c
SIF at pH 7.4
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fluid at pH 6.8 and 7.4 within a 2-h timeframe. The observed
release profiles did not conform to a diffusion model indicat-
ing that the complex interactions between the drug and clay
dictate the release kinetics.
The reported impact of smectite clay on the release behav-
iour of theophylline from multicomponent formulations is
highly variable [2, 3, 9]; although, in general, prolonged re-
lease is observed when the drug is incorporated under neutral
or acidic aqueous conditions. Dry-blended tableted formula-
tions do not exploit the modulating potential of smectite,
since, under these processing conditions, theophylline is not
able to interact with the clay [2].
Conclusions
The cationic form of theophylline was readily ion exchanged
into smectite clay under aqueous acidic conditions (pH 1.2) at
50 °C with a maximum uptake of 67 ± 2 mg g−1.
Characterisation of the drug-clay hybrid by powder X-ray
diffraction analysis, Fourier transform infrared spectroscopy,
differential scanning calorimetry and scanning electron mi-
croscopy confirmed that the theophylline had been intercalat-
ed into the clay in an amorphous form. The drug remained
bound within the clay under simulated gastric conditions
(pH 1.2), and the retarded release of approximately 40% of
the drug was observed in simulated intestinal fluid at pH 6.8
and 7.4 within a 2-h timeframe. The incomplete reversibility
of the intercalation process was attributed to chemisorption of
the drug within the clay lattice. These findings indicate that
smectite clay is a potentially suitable platform for the safe
passage of theophylline into the duodenum. Protection from
absorption in the stomach and subsequent prolonged release in
the small intestine are advantageous with respect to detrimen-
tal fluctuations in serum concentration.
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